Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States.

ABSTRACT:

Objectives

To evaluate the cost-effectiveness of a booster strategy in the United States.

Methods

We developed a decision-analytic Markov model of COVID-19 to evaluate the cost-effectiveness of a booster strategy of the Pfizer-BioNTech BNT162b2 (administered 6 months after the second dose) among older adults from a healthcare system perspective.

Results

Compared with 2 doses of BNT162b2 without a booster, the booster strategy in a 100,000 cohort of older adults would incur an additional cost of $3.4 million in vaccination cost but save $6.7 million in direct medical cost and gain 3.7 quality-adjusted life-years in 180 days. This corresponds to a benefit-cost ratio of 1.95 and a net monetary benefit of $3.4 million. Probabilistic sensitivity analysis indicates that a b

SUBMITTER: Li R 

PROVIDER: S-EPMC8938315 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature